Study #2023-0696
A phase 1b trial of YL-13027 in combination with Gemcitabine and Nab-paclitaxel in patients with refractory metastatic pancreatic cancer.
MD Anderson Study Status
Not Accepting
Treatment Agent
Gemcitabine, Nab-paclitaxel, YL-13027
Description
To learn if the study drug, YL-13027, is safe to give in combination with gemcitabine and nab-paclitaxel to participants with pancreatic cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Pancreatic Cancer
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-575-6618
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.